Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 195-196

  Fanouriakis, Antonis ^a   Vassilopoulos, Dimitrios ^b   Repa, Argyro ^a   Boumpas, Dimitrios T ^b   Sidiropoulos, Prodromos ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; METHOTREXATE; TENOFOVIR; VIRUS DNA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LATENT TUBERCULOSIS; LETTER; LIVER BIOPSY; LIVER HISTOLOGY; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REACTIVATION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCONJUGATES; RECURRENCE; VIRUS ACTIVATION;

EID: 84890906162     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket221     Document Type: Letter

References (9)

1. Ruderman EM, Pope RM. Drug insight: abatacept for the treatment of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2:654-60.
2. Germanidis G, Hytiroglou P, Zakalka M et al. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012;56:1420-1.
3. Kim PS, Ho GY, Prete PE et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 2012;64:1265-8.
4. Lan JL, Chen YM, Hsieh TY et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011;70:1719-25.
5. Winthrop KL, Calabrese LH. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 2011;70:1701-3.
6. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/antihepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54.
7. Charpin C, Guis S, Colson P et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179.
8. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5.
9. Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57.